News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK) (JOBS) Signs $330 Million Deal with Apeiron Biologics



2/3/2010 9:08:40 AM

Bookmark and Share

Dow Jones -- U.K.-based pharmaceuicals company GlaxoSmithKline PLC (GSK) has signed an exclusive license agreement with Apeiron Biologics to acquire the Austrian biotech company's rights to an early-stage lung disease drug, Apeiron said Wednesday. Under the deal, the world's second-largest drugmaker will get exclusive rights to APN01, an experimental medicine in Phase I development for the treatment of acute respiratory distress syndrome.

Read at Wall Street Journal
Read at News-Medical
Read at Reuters


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES